NCI Board of Scientific Advisors Convened Last Week
NCI's Board of Scientific Advisors (BSA) met November 7 on the NIH campus in Bethesda, MD.
Following a report from NCI Director Dr. Harold Varmus, NCI Deputy Director Dr. Doug Lowy, and Deputy Director for Clinical and Translational Research Dr. James Doroshow, attendees received a status update from the caBIG Oversight ad hoc Subcommittee, an update on the Chernobyl Tissue Bank, several presentations from the Division of Cancer Treatment and Diagnosis, and an overview of the NCI Center for Global Health.
Free Webinar Will Address Vitamin D and Cancer Prevention
NCI's Frontiers in Nutrition and Cancer Prevention Series will continue December 2 with a free webinar on "Vitamin D and Cancer Prevention: Shining Light on the Current Research," from 12:00 to 1:30 p.m. ET.
Emerging evidence suggests that higher vitamin D exposure may reduce the risk of certain cancers in some populations but increase the risk in others. Experts in the field will discuss current nutritional guidelines, strength of current research, and some potential mechanisms by which vitamin D may influence cancer risk. The invited speakers and the titles of their presentations are:
- "Vitamin D Overview: What Do We Know? What Do We Need to Know?"
Dr. Gabriela Riscuta, NCI Division of Cancer Prevention
- "Dietary Guidelines: How Much Is Enough? How Much Is Too Much?"
Dr. JoAnn Manson, Harvard Medical School
- "Clinical Research: Does Vitamin D Inhibit Cancer? How Strong Is the Clinical Evidence?"
Dr. Donald Trump, Roswell Park Cancer Institute
- "Basic Science: Potential Mechanisms for Vitamin D-Mediated Effects on Cancer Risk"
Dr. James Fleet, Purdue University
For more information and to register, visit the Frontiers in Nutrition and Cancer Prevention website.
State-of-the-Science Conference on Active Surveillance for Prostate Cancer Slated for December
On December 5–7, NCI and the NIH Office of Medical Applications of Research (OMAR) will convene a state-of-the-science conference on active surveillance for men with localized prostate cancer. The conference will take place at Natcher Conference Center on the NIH campus and will address the following key questions:
- How have the patient population and the natural history of prostate cancer diagnosed in the United States changed in the last 30 years?
- How are active surveillance and other observational strategies defined?
- What factors affect the offer of, acceptance of, and adherence to active surveillance?
- What short- and long-term health outcomes have patients with localized prostate cancer experienced with active surveillance versus immediate treatment with curative intent?
- What aspects of active surveillance (or watchful waiting) in localized prostate cancer need further research?
Invited experts will present information pertinent to these questions, and OMAR will prepare a systematic literature review. Conference attendees will have the opportunity to ask questions and provide statements during open discussion periods. After weighing the scientific evidence, an unbiased, independent panel will prepare and present a consensus statement addressing the key conference questions.
The conference is free and open to the public, but advance registration is recommended. For more information and to register, visit the conference website.